Ewing sarcoma family tumors (EFT) are highly malignant bone and soft tissue tumors that primarily affect children, adolescents and young adults. Despite aggressive local control measures and systemic chemotherapy, over a quarter of patients with localized tumors and nearly all patients with metastatic disease will relapse at distant sites following initial clinical remission. Unfortunately, the outlook for these patients is dismal and novel approaches to therapy are desperately needed. One ofthe biggest impediments to improving outcomes and quality of life for patients with EFT is our inability to predict who is at risk for metastatic relapse and to effectively identify and target the mechanisms that underlie this process. The studies outlined in this proposal aim to address these critical gaps in our knowledge. It is our overall goal to improve outcomes for patients with EFT by preventing metastatic relapse. In an effort to achieve this goal we will address three specific aims. First, we will use studies of cell lines to evaluate the role of CXCR4 positive EFT cells in mediating EFT metastasis. We will also determine if invasion downstream of CXCR4 is mediated by and dependent on RhoA. Second, we will test small molecule inhibitors of the RhoA/MKL transcriptional axis in vitro, ex vivo and in vivo to evaluate their efficacy as novel agents forthe prevention of EFT metastasis. Third, we will use retrospectively and prospectively collected EFT samples to validate whether expression of G-protein coupled receptors can be used to predict high-risk disease in newly diagnosed patients. Demonstration that CXCR4, CXCR7 and/or LGR5 expression can be used to identify patients at high risk of metastatic relapse will allow classification of patients into clinical risk categories. In turn, this will allow for treatment stratification and identification of patients who should be included in future trials that are designed to prevent relapse in high-risk patients.

Public Health Relevance

Currently, there is no way to predict which patients with Ewing's sarcoma (EFT) will relapse nor are there effective ways to cure this aggressive disease once it has spread. The studies in this proposal will improve our understanding of how EFT metastasizes, test the efficacy of novel drugs designed to prevent metastasis, and validate biomarkers that may be used to identify high risk patients at the time of diagnosis. If successful these studies will lead to fundamental changes in our approach to EFT therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA168512-03
Application #
8725490
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
3
Fiscal Year
2014
Total Cost
$235,177
Indirect Cost
$9,602
Name
Sarc
Department
Type
DUNS #
186146911
City
Ann Arbor
State
MI
Country
United States
Zip Code
48106
Nakayama, Robert; Zhang, Yi-Xiang; Czaplinski, Jeffrey T et al. (2016) Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget 7:16581-92
Goldstein, Seth D; Trucco, Matteo; Bautista Guzman, Wendy et al. (2016) A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. Oncotarget 7:21114-23
Schaefer, Inga-Marie; Fletcher, Christopher Dm; Hornick, Jason L (2016) Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol 29:4-13
Mariño-Enríquez, Adrián; Bovée, Judith V M G (2016) Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surg Pathol Clin 9:457-73
Tang, Qin; Moore, John C; Ignatius, Myron S et al. (2016) Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. Nat Commun 7:10358
Bobowski, Nina P; Baker, Laurence H (2016) The University of Michigan Sarcoma Survivorship Clinic: Preventing, Diagnosing, and Treating Chronic Illness for Improved Survival and Long-Term Health. J Adolesc Young Adult Oncol 5:211-4
Koehler, K; Liebner, D; Chen, J L (2016) TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol 27:539-43
Bid, Hemant K; Phelps, Doris A; Xaio, Linlin et al. (2016) The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther 15:1018-28
Simon, Priscilla S; Bardhan, Kankana; Chen, May R et al. (2016) NF-κB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression. Oncotarget 7:23395-415
De Rienzo, Assunta; Archer, Michael A; Yeap, Beow Y et al. (2016) Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. Cancer Res 76:319-28

Showing the most recent 10 out of 86 publications